Many people with CLL get a combination of therapies that can include chemotherapy, targeted therapy, and monoclonal antibodies. An example of a commonly used combination includes the chemo drugs cyclophosphamide (Cytoxan) and fludarabine (Fludara) plus the monoclonal antibody drug rituximab (Rituxan). ...
There are currently62 biosimilarsapproved by the U.S. Food and Drug Administration (FDA). The most recent biosimilar approval wasImuldosa(ustekinumab-srlf) on October 10, 2024. What is a Biosimilar? According the to FDA, a biosimilar is a biological product that is highly similar to, and ha...
Biologic response modifiers (another type of DMARD) such as abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), certolizumab and pegol (Cimzia) etanercept (Enbrel), infliximab (Remicade), golimumab (Simponi), and rituximab (Rituxan) Nonsteroidal anti-inflammatories (NSAIDs) such as ibupr...